Diabetes MellitusNCT06107816
A Fruit and Vegetable Prescription Program
A study testing F&V Rx alone and F&V Rx plus DSME/S in people with Diabetes Mellitus and Diabetes Complications, run by Milton S. Hershey Medical Center at 1 site in United States.
Trial summary
Dietary intake of fruits and vegetables (F\&V) is a cornerstone for the treatment of type 2 diabetes, however less than 16% of Hispanic adults consume the recommended number of servings each day. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diabetes Mellitus, Diabetes Complications
- What is being tested?
- F&V Rx alone and F&V Rx plus DSME/S
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 120 participants
- Where
- 1 siteUnited States
- Study dates
- 26 Jul 2024to Jul 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient at Penn State Health St. Joe's Medical Center
- Diagnosis of Type 2 Diabetes Mellitus greater than or equal to six months
- A1c level is greater than or equal to 7% (53 mmol/mol)
- Low income defined as enrolled in Supplemental Nutrition Assistance Program (SNAP), is uninsured or have Medicaid, or identifying as food insecure based on USDA criteria.
- Ability to give a blood sample
- Willing to respond to contacts from study staff over the study period
- Willing and able to give informed consent
- Can read and write in English or Spanish
Who cannot join
- Diagnosis of Type 2 Diabetes Mellitus less than six months
- Patients who have previously participated in the Veggie Rx program in the past year
- Patients who have attended any diabetes self-management education and support (DSME/S) sessions in the past year
- Women who are pregnant or who plan to become pregnant during the study period
- Any uncontrolled mental illness or substance abuse, or inpatient treatment for these in the past six months
- Any unstable or significant medical condition in the past 3 months (e.g. recent heart attack, stroke, DVT)
Show all 10Show fewer
- A1c level is less than 7%
- Does not speak English or Spanish
- Inability to provide informed consent
- Unable to give a blood sample
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Penn State Health St. Joseph Downtown Campus
Reading, Pennsylvania, 19601
Lisa Weaver, ljw34@psu.edu
About this study
Official title: A Pilot, 3-arm Randomized Controlled Trial of a Fruit and Vegetable Prescription Program for Patients With Type Two Diabetes
Dietary intake of fruits and vegetables (F\&V) is a cornerstone for the treatment of type 2 diabetes, however less than 16% of Hispanic adults consume the recommended number of servings each day. F\&V prescription (F\&V Rx) programs are embedded into clinical settings and provide patients with vouchers to purchase F\&V at local retailers. The proposed study aims to test the effects of a F\&V Rx on diabetes self-management education and support (DSME/S) uptake and retention, dietary intake of F\&V and diet quality, glucose control (hemoglobin A1c), and program implementation outcomes.
Read the detailed description
Consuming a nutrient-dense diet, rich in fruits and vegetables (F\&Vs) is at the cornerstone of type 2 diabetes (T2DM) treatment. Yet, among Hispanic adults, only 16% meet the recommended minimum F\&V intake recommendations and have higher rates of T2DM than non-Hispanic whites (16.6% versus 13.3%, respectively). F\&V Prescription (F\&V Rx) programs are embedded in clinical settings, target medically high-risk patients such as those with T2DM, and provide them with vouchers to purchase F\&V at local retailers. Preliminary F\&V Rx studies in patients with T2DM have found F\&V intake increases of 0.2-1.6 servings per day and hemoglobin A1c (A1c) reductions from 0.35-0.71% [3.8 -7.8 mmol/mol]. However, none of these studies included diabetes self-management education and support (DSME/S) which can lead to A1c decreases from 0.24% to 1.0% [2.6-10.9 mmol/mol]. The team conducted a pilot F\&V Rx study where DSME/S attendance was incentivized by providing a F\&V Rx at each session. Although DSME/S uptake is typically very low after referral (around 5-7%), the program had a 73% first session attendance rate. Further, at 7 months post-program, a clinically- and statistically-significant reduction was found in A1c of 1.3% [14.2 mmol/mol] (p=.001). Although the receipt of the F\&V Rx vouchers was contingent upon DSME/S attendance in the study, other T2DM-focused F\&V Rx studies did not have DSME/S attendance requirements and also saw A1c reductions. Thus, understanding the effect of a F\&V Rx on DSME/S uptake and retention with and without attendance requirements is a key design issue that must be evaluated. This proposal is in response to PAS 20-160 for short-term, pilot randomized controlled trials (RCTs) to acquire preliminary data regarding trial design. The team proposes a 3-Arm, 16-week, pilot RCT (n=120) for low-income adults (aged 18+) with T2DM (A1c >7% [53 mmol/mol]). The control group (n=40) will receive usual care (UC). The two intervention groups (n=40 each) will receive UC plus a F\&V Rx that is either independent of DSME/S attendance (F\&V Rx alone) or dependent on DSME/S attendance (F\&V Rx + DSME/S). First, the investigators will systematically explore the impact of a F\&V Rx on uptake and retention in DSME/S. Next, the investigators will explore changes in A1c, and diet-related outcomes. Finally, with implementation in mind, the investigators will use Proctor's implementation taxonomy, and the cultural adaptation framework from Castro et al., to assess program appropriateness, acceptability, and sustainability with both participants and clinical care providers. The study team and the Community Advisory Board (CAB) have the research, clinical expertise, and established retail network necessary to conduct a F\&V Rx trial in a low-income, Hispanic community. The findings of this trial will inform the design of a future, fully powered RCT and address gaps in knowledge related to how F\&V Rx programs impact T2DM-related outcomes. If effective, F\&V Rx programs have the potential to improve diabetes self-management and reduce the clinical burden of poor glycemic control, particularly in low-income, Hispanic communities.
- Conditions
- Diabetes Mellitus, Diabetes Complications
- Being tested
- Usual Care, F&V Rx alone, F&V Rx plus DSME/S
- Medical subject headings
- Diabetes Mellitus, Diabetes Complications
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Usual CareBehavioural
Visit with a primary care provider and referral for diabetes self-management education and support (DSME/S) sessions
F&V Rx aloneBehavioural
Usual Care plus four F\&V prescriptions that are independent of DSME/S attendance
F&V Rx plus DSME/SBehavioural
Usual Care plus four F\&V prescriptions that are dependent on DSME/S attendance
| Study group | Role | What they receive |
|---|---|---|
| Usual Care Control Group | Placebo comparator | Will receive usual care Receives: Behavioral: Usual Care |
| F&V Rx Alone Group | Active comparator | Will receive 4 monthly F\&V Rx vouchers regardless of their DSME/S attendance. Receives: Behavioral: F&V Rx alone |
| F&V Rx + DSME/S Group | Active comparator | Will receive monthly F\&V Rx vouchers starting at the first group session and they will receive additional F\&V Rx vouchers only when they attend a monthly DSME/S group (up to 4 total) Receives: Behavioral: F&V Rx plus DSME/S |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluate the impact of a F&V Rx on DSME/S uptake in low-income adults
Defined as the number of participants who attend any 1 DSME (# attend any 1 DSME/S session/total # randomized)
Measured: Throughout the 16 week intervention
Evaluate the impact of a F&V Rx on DSME/S retention in low-income adults.
Defined as % who attend >=75% of sessions (# attend >= 75% sessions/ # attended any 1 DSME/S session)
Measured: Throughout the 16 week intervention
Secondary outcomes (6)
Evaluate the impact of a F&V Rx on A1c (% and mg/dL)
Blood biomarker assessment will be taken and analyzed by the Penn State Health Clinical Labs.
Measured: Baseline (week 0) and follow up (week 16)
Evaluate the impact of a F&V Rx on Diabetes Self-Management
Measured by DSME questionnaire
Measured: Baseline (week 0) and follow up (week 16)
Evaluate the impact of a F&V Rx on Fruit and Vegetable Intake
Based on the 24-hour recalls
Measured: Baseline (week 0) and follow up (week 16)
Evaluate the impact of a F&V Rx on Healthy Eating index-2015
Based on the 24-hour recalls
Measured: Baseline (week 0) and follow up (week 16)
Evaluate the impact of a F&V Rx on Total plasma carotenoids (ng/mL)
Plasma carotenoids will be separated into the total and five individual concentrations (α-carotene, β-carotene, lutein, lycopene, and cryptoxanthin) using high-performance liquid chromatography methodology using our Sciex Exion LC-Sciex QTRAP 6500+ mass spectrometry system.
Measured: Baseline (week 0) and follow up (week 16)
Evaluate the impact of a F&V Rx on Food insecurity
Measured by the 18-item USDA Food Insecurity Questionnaire
Measured: Baseline (week 0) and follow up (week 16)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Oct 2023
- Study start26 Jul 2024
- Primary completionJul 2027 (estimated)
- Study completionJul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetes MellitusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Care provider, Investigator, Outcomes assessor
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Milton S. Hershey Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Susan Veldheer, Milton S. Hershey Medical Center
- Investigators
- Susan Veldheer, DEd, RD, Principal investigator, Penn State College of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06107816
- Sponsor's protocol ID
- 23681
- Other IDs
- R01DK132077-01A1
- Status last verified
- Nov 2025
- First submitted
- 16 Oct 2023
- Last updated
- 21 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Pilot, 3-arm Randomized Controlled Trial of a Fruit and Vegetable Prescription Program for Patients With Type Two Diabetes
- ClinicalTrials.gov ID
- NCT06107816
- Acronym / sponsor ID
- 23681
- Conditions
- Diabetes Mellitus, Diabetes Complications
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Milton S. Hershey Medical CenterUniversity, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Study start
- 26 Jul 2024 (actual)
- Primary completion
- Jul 2027 (estimated)
- Study completion
- Jul 2027 (estimated)
- First posted
- 30 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Dietary intake of fruits and vegetables (F\&V) is a cornerstone for the treatment of type 2 diabetes, however less than 16% of Hispanic adults consume the recommended number of servings each day. F\&V prescription (F\&V Rx) programs are embedded into clinical settings and provide patients with vouchers to purchase F\&V at local retailers. The proposed study aims to test the effects of a F\&V Rx on diabetes self-management education and support (DSME/S) uptake and retention, dietary intake of F\&V and diet quality, glucose control (hemoglobin A1c), and program implementation outcomes.
Detailed description
Consuming a nutrient-dense diet, rich in fruits and vegetables (F\&Vs) is at the cornerstone of type 2 diabetes (T2DM) treatment. Yet, among Hispanic adults, only 16% meet the recommended minimum F\&V intake recommendations and have higher rates of T2DM than non-Hispanic whites (16.6% versus 13.3%, respectively). F\&V Prescription (F\&V Rx) programs are embedded in clinical settings, target medically high-risk patients such as those with T2DM, and provide them with vouchers to purchase F\&V at local retailers. Preliminary F\&V Rx studies in patients with T2DM have found F\&V intake increases of 0.2-1.6 servings per day and hemoglobin A1c (A1c) reductions from 0.35-0.71% [3.8 -7.8 mmol/mol]. However, none of these studies included diabetes self-management education and support (DSME/S) which can lead to A1c decreases from 0.24% to 1.0% [2.6-10.9 mmol/mol]. The team conducted a pilot F\&V Rx study where DSME/S attendance was incentivized by providing a F\&V Rx at each session. Although DSME/S uptake is typically very low after referral (around 5-7%), the program had a 73% first session attendance rate. Further, at 7 months post-program, a clinically- and statistically-significant reduction was found in A1c of 1.3% [14.2 mmol/mol] (p=.001). Although the receipt of the F\&V Rx vouchers was contingent upon DSME/S attendance in the study, other T2DM-focused F\&V Rx studies did not have DSME/S attendance requirements and also saw A1c reductions. Thus, understanding the effect of a F\&V Rx on DSME/S uptake and retention with and without attendance requirements is a key design issue that must be evaluated. This proposal is in response to PAS 20-160 for short-term, pilot randomized controlled trials (RCTs) to acquire preliminary data regarding trial design. The team proposes a 3-Arm, 16-week, pilot RCT (n=120) for low-income adults (aged 18+) with T2DM (A1c >7% [53 mmol/mol]). The control group (n=40) will receive usual care (UC). The two intervention groups (n=40 each) will receive UC plus a F\&V Rx that is either independent of DSME/S attendance (F\&V Rx alone) or dependent on DSME/S attendance (F\&V Rx + DSME/S). First, the investigators will systematically explore the impact of a F\&V Rx on uptake and retention in DSME/S. Next, the investigators will explore changes in A1c, and diet-related outcomes. Finally, with implementation in mind, the investigators will use Proctor's implementation taxonomy, and the cultural adaptation framework from Castro et al., to assess program appropriateness, acceptability, and sustainability with both participants and clinical care providers. The study team and the Community Advisory Board (CAB) have the research, clinical expertise, and established retail network necessary to conduct a F\&V Rx trial in a low-income, Hispanic community. The findings of this trial will inform the design of a future, fully powered RCT and address gaps in knowledge related to how F\&V Rx programs impact T2DM-related outcomes. If effective, F\&V Rx programs have the potential to improve diabetes self-management and reduce the clinical burden of poor glycemic control, particularly in low-income, Hispanic communities.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Usual Care Control Group | Placebo comparator | Behavioral: Usual CareWill receive usual care |
| F&V Rx Alone Group | Active comparator | Behavioral: F&V Rx aloneWill receive 4 monthly F\&V Rx vouchers regardless of their DSME/S attendance. |
| F&V Rx + DSME/S Group | Active comparator | Behavioral: F&V Rx plus DSME/SWill receive monthly F\&V Rx vouchers starting at the first group session and they will receive additional F\&V Rx vouchers only when they attend a monthly DSME/S group (up to 4 total) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Patient at Penn State Health St. Joe's Medical Center
- Diagnosis of Type 2 Diabetes Mellitus greater than or equal to six months
- A1c level is greater than or equal to 7% (53 mmol/mol)
- Low income defined as enrolled in Supplemental Nutrition Assistance Program (SNAP), is uninsured or have Medicaid, or identifying as food insecure based on USDA criteria.
- Ability to give a blood sample
Key exclusion criteria (10 listed)
- Diagnosis of Type 2 Diabetes Mellitus less than six months
- Patients who have previously participated in the Veggie Rx program in the past year
- Patients who have attended any diabetes self-management education and support (DSME/S) sessions in the past year
- Women who are pregnant or who plan to become pregnant during the study period
- Any uncontrolled mental illness or substance abuse, or inpatient treatment for these in the past six months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Usual CareVisit with a primary care provider and referral for diabetes self-management education and support (DSME/S) sessions | Behavioural | Usual Care Control Group |
| F&V Rx aloneUsual Care plus four F\&V prescriptions that are independent of DSME/S attendance | Behavioural | F&V Rx Alone Group |
| F&V Rx plus DSME/SUsual Care plus four F\&V prescriptions that are dependent on DSME/S attendance | Behavioural | F&V Rx + DSME/S Group |
Primary outcome
Evaluate the impact of a F&V Rx on DSME/S uptake in low-income adults
Time frame: Throughout the 16 week intervention
Defined as the number of participants who attend any 1 DSME (# attend any 1 DSME/S session/total # randomized)
Evaluate the impact of a F&V Rx on DSME/S retention in low-income adults.
Time frame: Throughout the 16 week intervention
Defined as % who attend >=75% of sessions (# attend >= 75% sessions/ # attended any 1 DSME/S session)
6 secondary outcomes
Evaluate the impact of a F&V Rx on A1c (% and mg/dL)
Time frame: Baseline (week 0) and follow up (week 16)
Evaluate the impact of a F&V Rx on Diabetes Self-Management
Time frame: Baseline (week 0) and follow up (week 16)
Evaluate the impact of a F&V Rx on Fruit and Vegetable Intake
Time frame: Baseline (week 0) and follow up (week 16)
Evaluate the impact of a F&V Rx on Healthy Eating index-2015
Time frame: Baseline (week 0) and follow up (week 16)
Evaluate the impact of a F&V Rx on Total plasma carotenoids (ng/mL)
Time frame: Baseline (week 0) and follow up (week 16)
Evaluate the impact of a F&V Rx on Food insecurity
Time frame: Baseline (week 0) and follow up (week 16)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Nov 2025.
- Individual participant dataSharing planned: No
Related trials for Diabetes Mellitus
Recruiting
Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Not yet recruitingPhase 2
Effects of Meal Macronutrients on Postprandial Lipids
Nephrotic Syndrome, Lipodystrophy
Enrolling by invitation
MTM2MTG Pilot Ancillary Study
Diet, Healthy, HbA1c
Active, not recruitingPhase 3
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
Lipodystrophy, Diabetes
Active, not recruitingPhase 2
Islet Cell Transplant for Type 1 Diabetes
Type 1 Diabetes Mellitus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Susan Veldheer, DEd, RD principal investigator
Penn State College of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing F&V Rx alone and F&V Rx plus DSME/S in people with Diabetes Mellitus and Diabetes Complications, run by Milton S. Hershey Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Susan Veldheer, DEd, RD (717-531-5625, sveldheer@pennstatehealth.psu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluate the impact of a F&V Rx on DSME/S uptake in low-income adults (time frame: Throughout the 16 week intervention). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2025.